Dr. Sanjit Singh Lamba Reveals How Document Template Errors Cost Pharmaceutical Companies Massive Financial Losses
A sobering case study presented at analytica India Lab 2025 revealed how seemingly minor regulatory submission errors can cascade into catastrophic business consequences, with one pharmaceutical company suffering a $3 billion loss due to document formatting inconsistencies and outdated template usage. Dr. Sanjit Singh Lamba, Senior Advisor and Managing Partner at Trillgum Consulting, used real-world examples to demonstrate how quality risk management principles must extend beyond manufacturing operations to encompass comprehensive regulatory compliance strategies.
Hidden Vulnerability in Regulatory Submissions
Lamba’s presentation challenged common assumptions about regulatory risk by focusing on Drug Regulatory Affairs submission compliance rather than traditional GMP-related quality issues. His central case study involved a generic manufacturer whose Marketing Authorization Application (MAA) submitted under the EMA centralized procedure was rejected due to fundamental document inconsistencies that appeared minor but created significant patient safety concerns.
“This MA was rejected. First it was delayed, and it was told it was to be delayed, and finally it was rejected due to inconsistent product information across the SmPC [Summary of Product Characteristics], PIL [Patient Information Leaflet], labeling, and also misalignment with the QRD [Quality Review of Documents],” Lamba explained, describing how document formatting errors escalated to regulatory rejection.
The case revealed a critical vulnerability in pharmaceutical regulatory processes: the assumption that sophisticated companies with extensive regulatory experience are immune to basic submission errors. The affected organization possessed substantial technical capabilities and regulatory expertise, yet failed to implement adequate quality controls for document consistency and template compliance.
Outdated QRD Requirements
The core failure involved the company’s use of outdated Quality Review of Documents (QRD) templates that no longer met current EMA requirements. This seemingly administrative oversight created a cascade of compliance failures including inconsistent product information across multiple document types, mismatched dosing instructions between different submission components, missing mandatory safety warnings, and translation errors that compounded formatting problems.
Lamba emphasized that regulatory agencies regularly update template requirements, and pharmaceutical companies must implement systematic processes to ensure current template usage across all submission documents. The failure to maintain template currency represents a fundamental breakdown in regulatory intelligence and document control processes.
“There was a failure to use the latest QRD template which was issued. The submitted documents were outdated format,” Lamba noted, highlighting how administrative oversight can undermine extensive scientific and technical preparation for regulatory submissions.
The RPN Framework Applied to Regulatory Compliance
The presentation demonstrated how traditional Quality Risk Management principles from ICH Q9 can be systematically applied to regulatory submission processes using Risk Priority Number (RPN) calculations based on Occurrence × Severity × Detection scoring. Lamba’s framework provides structured approaches to identifying and prioritizing regulatory compliance risks that extend beyond manufacturing-focused quality systems.
The risk assessment methodology categorizes severity levels from catastrophic (major regulatory action including consent decrees or product seizures) through critical (market withdrawal or recalls), moderate (regulatory information requests requiring corrective action), marginal (regulatory notification without product compromise), to negligible (minimal regulatory impact).
Probability assessments range from rare occurrences (every 10-30 years) to almost certain events (multiple times annually), enabling pharmaceutical companies to prioritize risk mitigation resources based on quantified likelihood and impact calculations.
Regulatory Risk Categories
Lamba’s analysis revealed multiple high-risk categories in regulatory submissions that require systematic control measures:
Template and Documentation Risks: Outdated QRD templates, inconsistent product information across submission documents, and misaligned formatting requirements create immediate rejection risks that can be prevented through version control systems and cross-functional review processes.
Translation and Localization Risks: Unverified translation errors, cultural adaptation failures, and regulatory requirement misinterpretation across multiple jurisdictions demand specialized expertise and systematic validation approaches.
Process and Oversight Risks: Inadequate internal review procedures, lack of cross-functional submission teams, and insufficient regulatory intelligence updating create systemic vulnerabilities that compound individual document errors.
Timing and Coordination Risks: Delayed submissions, mismatched data across submission components, and inadequate regulatory agency communication can transform minor issues into major compliance failures.
The $3 Billion Lesson
The presentation’s most striking element was the revelation that regulatory submission errors can generate financial consequences comparable to major manufacturing failures or clinical trial setbacks. The cited $3 billion loss associated with regulatory compliance failures demonstrates how administrative errors can create business impacts rivaling product recalls or FDA consent decrees.
Lamba emphasized that reputation damage often exceeds immediate financial losses, as regulatory submission failures signal fundamental quality system breakdowns that affect investor confidence, partnership opportunities, and future regulatory interactions. Companies that demonstrate systematic regulatory compliance failures face enhanced scrutiny from regulatory agencies and reduced credibility in subsequent submissions.
The case study illustrated how regulatory compliance failures create cascading business consequences including submission delays that miss market opportunity windows, increased regulatory review costs and consultation expenses, competitive disadvantage during exclusivity periods, and long-term relationship damage with regulatory agencies.
Risk Mitigation: Systematic Compliance Controls
The presentation outlined comprehensive risk mitigation strategies that pharmaceutical companies can implement to prevent regulatory submission failures:
Centralized Template Management: Implementing systematic processes to monitor regulatory agency template updates and ensure current version usage across all submission documents requires dedicated regulatory intelligence capabilities and version control systems.
Cross-Functional Review Teams: Establishing mandatory review processes involving regulatory, medical writing, quality assurance, and regional regulatory specialists enables comprehensive submission validation before agency submission.
Mock Audit and Pre-Submission Validation: Conducting internal audit processes that simulate regulatory review criteria and validate submission completeness against current agency requirements can identify potential issues before formal submission.
Translation Validation and Readability Testing: Implementing systematic translation verification processes and conducting readability testing with target patient populations ensures accurate communication of safety and efficacy information.
Submission Tracking and Project Management: Utilizing comprehensive project management systems that track submission components, review status, and regulatory timelines prevents coordination failures and timing-related compliance issues.
Implementation Challenges
Lamba acknowledged that implementing comprehensive regulatory risk management requires overcoming significant organizational barriers, particularly in companies where regulatory compliance is viewed as administrative rather than strategic function. Many pharmaceutical organizations focus risk management resources on manufacturing and clinical areas while treating regulatory submissions as routine administrative processes.
The cultural challenge involves convincing senior leadership that regulatory compliance deserves risk management investment comparable to manufacturing quality systems. Organizations must recognize that regulatory submission failures can generate business consequences equivalent to manufacturing compliance failures or clinical trial setbacks.
Additionally, the technical complexity of modern regulatory requirements across multiple global jurisdictions creates substantial expertise requirements that many pharmaceutical companies struggle to maintain internally. The need for specialized regulatory intelligence, template management, and cross-jurisdictional compliance knowledge demands significant human capital investment.
Systematic Risk Assessment
The presentation advocated for systematic risk assessment approaches that identify potential regulatory compliance failures before they occur rather than reactive responses to regulatory feedback. This proactive approach requires pharmaceutical companies to invest in regulatory intelligence capabilities, systematic compliance monitoring, and comprehensive risk assessment methodologies.
Lamba’s framework demonstrates how traditional quality risk management tools can be adapted for regulatory compliance applications, enabling pharmaceutical companies to quantify and prioritize regulatory risks using established risk assessment methodologies. This systematic approach provides objective criteria for resource allocation and risk mitigation prioritization.
The emphasis on quantified risk assessment using RPN calculations and risk matrices enables pharmaceutical companies to make data-driven decisions about regulatory compliance investments and demonstrate the business value of regulatory risk management programs.
Industry-Wide Implications
The case study revelations suggest that regulatory compliance excellence represents a significant competitive advantage in pharmaceutical markets where submission timing and approval success directly affect market access and revenue generation. Companies that implement comprehensive regulatory risk management systems can achieve faster approval timelines, reduced regulatory review cycles, and enhanced credibility with regulatory agencies.
Conversely, companies that treat regulatory compliance as administrative overhead rather than strategic capability face increasing risks of submission failures, regulatory delays, and competitive disadvantage. The presented case studies demonstrate that regulatory compliance failures can generate financial consequences rivaling product development setbacks or manufacturing compliance issues.
The presentation suggested that pharmaceutical industry consolidation and increasing regulatory complexity will amplify the competitive advantages of regulatory compliance excellence, making systematic risk management essential for sustained business success rather than optional administrative enhancement.
Integrated Risk Management Systems
Lamba’s presentation positioned regulatory compliance risk management as essential component of comprehensive pharmaceutical quality systems rather than isolated administrative function. The integration of regulatory risk assessment with manufacturing quality systems, clinical development risk management, and business continuity planning creates holistic risk management capabilities that address interconnected pharmaceutical business risks.
The systematic approach to regulatory risk management provides frameworks for pharmaceutical companies to identify, assess, and mitigate regulatory compliance risks using established risk management methodologies. This integration enables consistent risk assessment approaches across pharmaceutical operations while recognizing the unique characteristics of regulatory compliance risks.
The emphasis on quantified risk assessment and systematic mitigation strategies demonstrates how pharmaceutical companies can transform regulatory compliance from reactive administrative burden to proactive competitive advantage through systematic risk management implementation.
- Naresh Nunna
